Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells.

Conclusions: This study suggested that combination therapy with metformin and nilotinib may have clinical benefits of enhancing antileukemia efficacy and overcoming resistance to nilotinib.
PMID: 32241082 [PubMed - as supplied by publisher]

Source: The Korean Journal of Internal Medicine - April 2, 2020 Category: Internal Medicine Authors: Na YJ, Yu ES, Kim DS, Lee DH, Oh SC, Choi CW Tags: Korean J Intern Med Source Type: research